Lista de obras - Teresa Troiani - Dominio Público Uruguay

A Preliminary Study for Quantitative Assessment with HFUS (High- Frequency Ultrasound) of Nodular Skin Melanoma Breslow Thickness in Adults Before Surgery: Interdisciplinary Team Experience

artículo científico publicado en 2020

A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer.

artículo científico publicado en 2011

A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer

scientific article published on 03 January 2012

AXL is an oncotarget in human colorectal cancer.

artículo científico publicado en 2015

Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases

artículo científico publicado en 2006

Antiangiogenic drugs in non-small cell lung cancer treatment.

artículo científico publicado en 2006

Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines.

artículo científico publicado en 2001

Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

artículo científico publicado en 2004

Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.

artículo científico publicado en 2005

Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors

artículo científico publicado en 2011

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

artículo científico publicado en 2003

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors

artículo científico publicado en 2011

Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer.

artículo científico publicado en 2007

Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.

artículo científico publicado en 2014

Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.

artículo científico publicado en 2003

Comparative Study of NGS Platform Ion Torrent Personal Genome Machine and Therascreen Rotor-Gene Q for the Detection of Somatic Variants in Cancer

artículo científico publicado en 2020

Critical appraisal of the use of regorafenib in the management of colorectal cancer.

artículo científico publicado en 2013

Erlotinib in cancer treatment.

artículo científico publicado en 2007

External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life.

artículo científico publicado en 2003

Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass.

artículo científico publicado en 2007

Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.

artículo científico publicado en 2015

Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells

artículo científico publicado en 2013

Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.

artículo científico publicado en 2005

Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.

artículo científico publicado en 2007

Lymphomatoid papulosis

scientific article published on 20 January 2020

Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models

artículo científico publicado en 2015

Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells.

artículo científico publicado en 2018

Metformin in lung cancer: rationale for a combination therapy

artículo científico publicado en 2013

Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer.

artículo científico publicado en 2014

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations

artículo científico publicado en 2020

Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.

artículo científico publicado en 2013

Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care.

artículo científico publicado en 2007

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

artículo científico publicado en 2015

Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer

artículo científico publicado en 2006

Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) in the Elderly and the Importance of Sport Activity Training

artículo científico publicado en 2020

Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.

artículo científico publicado en 2015

Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.

artículo científico publicado en 2014

SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.

artículo científico publicado en 2015

Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.

artículo científico publicado en 2005

Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells.

artículo científico publicado en 2008

Spectroscopic Characterization and Cytotoxicity Assessment towards Human Colon Cancer Cell Lines of Acylated Cycloartane Glycosides from Astragalus boeticus L

scientific article published on 03 May 2019

Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.

artículo científico publicado en 2006

Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.

artículo científico publicado en 2013

Targeting EGFR in pancreatic cancer treatment.

artículo científico publicado en 2012

The use of xenograft models for the selection of cancer treatments with the EGFR as an example.

artículo científico publicado en 2008

Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments.

artículo científico publicado en 2004

Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer

artículo científico

Lista de obras de Teresa Troiani

A Preliminary Study for Quantitative Assessment with HFUS (High- Frequency Ultrasound) of Nodular Skin Melanoma Breslow Thickness in Adults Before Surgery: Interdisciplinary Team Experience

A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer.

A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer

AXL is an oncotarget in human colorectal cancer.

Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases

Antiangiogenic drugs in non-small cell lung cancer treatment.

Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines.

Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.

Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors

Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer.

Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.

Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.

Comparative Study of NGS Platform Ion Torrent Personal Genome Machine and Therascreen Rotor-Gene Q for the Detection of Somatic Variants in Cancer

Critical appraisal of the use of regorafenib in the management of colorectal cancer.

Erlotinib in cancer treatment.

External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life.

Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass.

Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.

Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells

Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.

Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.

Lymphomatoid papulosis

Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models

Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells.

Metformin in lung cancer: rationale for a combination therapy

Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer.

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations

Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.

Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care.

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer

Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) in the Elderly and the Importance of Sport Activity Training

Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.

Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.

SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.

Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.

Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells.

Spectroscopic Characterization and Cytotoxicity Assessment towards Human Colon Cancer Cell Lines of Acylated Cycloartane Glycosides from Astragalus boeticus L

Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.

Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.

Targeting EGFR in pancreatic cancer treatment.

The use of xenograft models for the selection of cancer treatments with the EGFR as an example.

Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments.

Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer